Rigel Pharmaceuticals | RIGL - Ebitda


Rigel Pharmaceuticals reported $-4.17M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 3.86B 1.28B Mar/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Celldex Therapeutics USD -83.58M 2.76M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Veracyte USD 43.96M 1.16M Jun/2026